37 2 CISPLATIN-INDUCED ACUTE KIDNEY INJURY | PART ONE Primary LA-SCCHN tumor site was the oral cavity or oropharynx in 71% of patients, and the hypopharynx in 12%. Fifty-six percent of patients had T3 or T4 LA-SCCHN, and 85% had node-positive disease. Mean sCr value was 66 µmol/l (Standard Deviation, SD 12). Eighty-five patients (69%) were re-admitted at least once for AKI during CRT. AKI was reported in 85 patients (69%) with 112 episodes of AKI. Sixty of 85 patients (71%) experienced one AKI episode; 20 patients (29%) experienced ≥ 2 AKI episodes. Ninetythree (83%) AKI episodes were stage 1, 13 (12%) were stage 2, and 6 (5%) AKI episodes were stage 3. Eighty-six patients (69%) received all three preplanned courses of cisplatin (cumulative dose 300 mg/m2) without dose adjustment (Fig 1). Figure 1. Patient disposition Thirty-eight patients (31%) prematurely discontinued cisplatin treatment; seven patients after the first cycle, and 31 patients after two cycles of cisplatin. Reasons for discontinuation was AKI in 28 patients (74%) and infection/sepsis in 4 patients (11%). Median cumulative dose of cisplatin was 259 mg/m2 (86% of preplanned dose) in the AKI group and 269 mg/ m2 (90% of preplanned dose) in the non-AKI group (p= 0.36). All patients but two (sepsis, n= 1; patient refusal, n= 1) received the preplanned, scheduled radiotherapy dose.
RkJQdWJsaXNoZXIy MjY0ODMw